8:00 AM - 9:00 AM

Breakfast & Analyst One-to-One Meetings

AI Café

Moving AI Tools out of the "Science of AI" to Tools that Impact "Pharma Science"


9:00 AM - 9:25 AM

Breaking through the Bottleneck: A multi-omics Perspective on How Best to Use Data

How to best use data seems simple and straightforward, but in reality it is complicated and ambiguous. This high-powered session will cover how to best generate, evaluate and translate biomedical data into drug targets that lead to transformational, safe and effective medicines.
  • What AI/ML tools can support the phases of transitioning data from information to insight
  • What are the underlying infrastructure and data management systems that need to be in place to achieve these outcomes
  • How do you create a data ecosystem that translates and integrates diverse data from both internal and external partners into insight
  • AI tools that you can deploy to ensure data is an ongoing entity that evolves, continues to learn, and grows

Speakers

  • Alex Aronov, Ph.D.

    Alex Aronov, Ph.D. Senior Director and Head, Enterprise Data Science Vertex Pharmaceuticals

  • Dr. Gunaretnam (Guna) Rajagopal

    Dr. Gunaretnam (Guna) Rajagopal VP Global Head – Computational Sciences, Discovery Sciences Janssen Research & Development, A Johnson & Johnson Company


9:25 AM - 9:55 AM

Data is the New Key Asset: An Interactive Discussion with CDOs

This session puts a spotlight on the challenges all organizations are facing, but that are particularly prevalent in healthcare organizations.  Join the conversation and help to facilitate and encourage change.  We hope by the end of this discussion you will be able to commit to 1-2 things that you can influence in your role over the next year to make progress in more effective management of your data. Discussion points include:  
  • Is it important to develop core technical capabilities in-house or can you rely heavily on consultants and outsourcing?
  • How do you move beyond legacy systems that follow a linear process of development to incorporate more effective methods like agile and sprint?
  • What resources do you need to be able to achieve a global data view to be able to make better decisions?
    • Where do you pull your data from?
    • How do you store it?
    • What is the most effective way to approach data definitions?
  • What are the ethical issues around data and data sharing that you need to be aware of?
  • What can be learned from other industries and companies like Netflix and Coca-Cola about effective data management?

Moderator

  • Mike Townsend

    Mike Townsend Research Manager, Life Sciences Commercial Strategies IDC Health Insights

Speakers

  • Lihua Yu, Ph.D.

    Lihua Yu, Ph.D. President, Chief Data Science Officer H3 Biomedicine Inc.


9:55 AM - 10:20 AM

Real-World Evidence and AI: Where are We Now and How Can We Take the Next Steps Forward to Directly Impact Care?

This session will focus on the kind of real world data that is needed to realize the potential of AI. With so much opportunity for progress, prioritizing projects is a critical step in delivering on results. Speakers will help identify what types of questions are easier to answer and which are harder in order to help you choose the projects that will result in near term ROI. Using case study examples from two therapeutic areas, discussion will cover these questions and more:  
  • What are the most reliable sources of real world data?
  • How does data need to be curated to be useful?
  • Where are we on the path to directly impacting care?
  • What needs to be done to get to the next phase in realizing the potential of AI through the use of real world evidence?

Moderator

  • Mike Townsend

    Mike Townsend Research Manager, Life Sciences Commercial Strategies IDC Health Insights

  • Marisa Co

    Marisa Co Vice President R&D Business Insights & Analytics Bristol-Myers Squibb

Speakers

  • Marisa Co

    Marisa Co Vice President R&D Business Insights & Analytics Bristol-Myers Squibb


10:20 AM - 10:50 AM

Morning Refreshments & Analyst One-to-One Meetings

AI Café

10:50 AM - 11:15 AM

The Power of GANs and RL in pharma R&D: from Experimentally-Validated End-to-End Drug Discovery Pipelines to Generation of Synthetic Patients

GANs and GAN-RL systems are powerful tool for a plethora of drug discovery and biomarker development applications. The application of GANs for small molecule generation was pioneered by the scientists at Insilico Medicine with the first peer-reviewed paper titled "The cornucopia of meaningful leads" followed by series of the theoretical and experimental research papers. This session will cover usage of GAN’s by biopharmaceutical companies for:
  • Synthetic data generation
  • Extracting useful targets
  • Building causal graphs
  • Simulating drug response and CRISPR data
  • Generation of molecules with specific properties
  • Generating molecules to a specific objective

11:15 AM - 11:45 AM

How do you Build/Modify your Organization around Data Strategy – Know what questions to ASK!

Speakers


11:45 AM - 12:00 PM

Chair's Closing Remarks